The toll-like receptor pathway: A novel mechanism of infection-induced carcinogenesis of prostate epithelial cells

Prostate

Volumn 68, Issue 2, 2008, Pages 223-229

  Kundu, Shilajit D ^a   Lee, Chung ^a   Billips, Benjamin K ^a   Habermacher, Geoffrey M ^a   Zhang, Qiang ^a   Liu, Victoria ^a   Wong, Larry Y ^a   Klumpp, David J ^a   Thumbikat, Praveen ^a,b  

^a NORTHWESTERN UNIVERSITY   (United States)

^b Tarry Building 16 703 ^*  (United States)

Author keywords

Epithelia; Infection; Proliferation; Prostate; Prostatitis

Indexed keywords

CPG OLIGODEOXYNUCLEOTIDE; DNA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LACTATE DEHYDROGENASE; LIPOPOLYSACCHARIDE; SMALL INTERFERING RNA; TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 9; TUMOR NECROSIS FACTOR ALPHA;

APOPTOSIS; ARTICLE; BACTERIUM; CARCINOGENESIS; CELL CULTURE; CELL DEATH; CELL FUNCTION; CELL PROLIFERATION; CONCENTRATION RESPONSE; DNA VIRUS; ENZYME RELEASE; ESCHERICHIA COLI; GENETIC TRANSFECTION; GRAM NEGATIVE BACTERIUM; HERPES SIMPLEX VIRUS; HUMAN; HUMAN CELL; IN VITRO STUDY; INFLAMMATION; MALE; MALIGNANT TRANSFORMATION; NICK END LABELING; PATHOGENESIS; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE EPITHELIUM; PROTEIN EXPRESSION; TIME; UROGENITAL SYSTEM; UROGENITAL TRACT INFECTION; VIRUS; WART VIRUS;

CELL LINE; CELL PROLIFERATION; CELL TRANSFORMATION, NEOPLASTIC; CPG ISLANDS; DOSE-RESPONSE RELATIONSHIP, DRUG; EPITHELIAL CELLS; ESCHERICHIA COLI; HUMANS; L-LACTATE DEHYDROGENASE; LIPOPOLYSACCHARIDES; MALE; NF-KAPPA B; PAPILLOMAVIRIDAE; PROSTATE; PROSTATIC NEOPLASMS; SIMPLEXVIRUS; TOLL-LIKE RECEPTOR 4; TOLL-LIKE RECEPTOR 9; TOLL-LIKE RECEPTORS;

EID: 38749139248     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.20710     Document Type: Article

References (21)

1. Landis SH, Murray T, Bolden S, Wingo PA. Cancer statistics 1999. CA Cancer J Clin 1999;49(1):8-31.
2. Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, Ghafoor A, Feuer EJ, Thun MJ. Cancer Statistics 2005. CA Cancer J Clin 2005;55(1):10-30.
3. Dennis LK, Lynch CF, Torner JC. Epidemiologic association between prostatitis and prostate cancer. Urology 2002;60(1):78-83.
4. Dennis LK, Dawson DV. Meta-analysis of measures of sexual activity and prostate cancer. Epidemiology 2002;13(1):72-79.
5. Nelson WG, DeWeese TL, DeMarzo AM. The diet, prostate inflammation, and the development of prostate cancer. Cancer Metastasis Rev 2002;21(1):3-16.
6. Akira S, Uematsu S, Takeuchi O. Pathogen recognition and innate immunity. Cell 2006;124(4):783-801.
7. Medzhitov R, Janeway C. Innate Immunity N Engl J Med 2000;343(5):338-344.
8. Sun J, Wiklund F, Zheng SL, Chang B, Balter K, Li L, Johansson J-E, Li G, Adami H-O, Liu W, Tolin A, Turner AR, Meyers DA, Isaacs WB, Xu J, Gronberg H. Sequence variants in toll-like receptor gene cluster (TLR6-TLR1-TLR10) and prostate cancer risk. J Natl Cancer Inst 2005;97(7):525-532.
9. Zheng SL, Augustsson-Balter K, Chang B, Hedelin M, Li L, Adami HO, Bensen J, Li G, Johnasson JE, Turner AR, Adams TS, Meyers DA, Isaacs WB, Xu J, Gronberg H. Sequence variants of toll-like receptor 4 are associated with prostate cancer risk: results from the CAncer Prostate in Sweden Study. Cancer Res 2004;64(8):2918-2922.
10. Palapattu GS, Sutcliffe S, Bastian PJ, Platz EA, De Marzo AM, Isaacs WB, Nelson WG. Prostate carcinogenesis and inflammation: emerging insights. Carcinogenesis 2005;26(7):1170-1181.
11. Chen Q, Fischer A, Reagan JD, Yan L, Ames BN. Oxidative DNA damage and senescence of human diploid fibroblast cells. Proc Natl Acad Sci 1995;92(10):4337-4341.
12. Nickel JC, Moon T. Chronic bacterial prostatitis: An evolving clinical enigma. Urology 2005;66(1):2-8.
13. Tanner MA, Shoskes D, Shahed A, Pace NR. Prevalence of corynebacterial 16S rRNA sequences in patients with bacterial and "nonbacterial" prostatitis. J Clin Microbiol 1999;37(6):1863-1870.
14. Serth J, Panitz F, Paeslack U, Kuczyk MA, Jonas U. Increased levels of human papillomavirus type 16 DNA in a subset of prostate cancers. Cancer Res 1999;59(4):823-825.
15. Kuczyk M, Serth J, Machtens S, Jonas U. Detection of viral HPV 16 DNA in prostate cancer and benign prostatic hyperplasia by quantitative PCR-directed analysis. Prostate Cancer Prostatic Dis 2000;3(S1):S23.
16. Boldogh I, Baskar JF, Mar EC, Huang ES. Human cytomegalovirus and herpes simplex type 2 virus in normal and adenocarcinomatous prostate glands. J Natl Cancer Inst 1983;70(5):819-826.
17. Urisman A, Molinaro RJ, Fischer N, Plummer SJ, Casey G, Klein EA, Malathi K, Magi-Galluzzi C, Tubbs RR, Ganem D, Silverman RH, DeRisi JL. Identification of a novel Gammaretrovirus in prostate tumors of patients homozygous for R462Q RNASEL variant. PLoS Pathog 2006;2(3):e25.
18. DeMarzo AM, Meeker AK, Zha S, Luo J, Nakayama M, Platz EA, Isaacs WB, Nelson WG. Human prostate cancer precursors and pathobiology. Urology 2003;62 (5 Suppl 1):55-62.
19. Mirchandani D, Zheng J, Miller GJ, Ghosh AK, Shibata DK, Cote RJ, Roy-Burman P. Heterogeneity in intratumor distribution of p53 mutations in human prostate cancer. Am J Pathol 1995;147(1):92-101.
20. Suh J, Rabson AB. NF-kappaB activation in human prostate cancer: important mediator or epiphenomenon? J Cell Biochem 2004;91(1):100-117.
21. Li Q, Withoff S, Verma IM. Inflammation-associated cancer: NF-[kappa]B is the lynchpin. Trends Immunol 2005;26(6):318-325.